Rapid Antibody Response after Vaccination with a Virosomal Hepatitis A Vaccine

Ambrosch, F; Finkel, Beatriz; Herzog, Christian; Koren, Ana; Kollaritsch, Herwig

doi:10.1007/s15010-004-3147-4

Cited by 20 publications

(7 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This result is consistent with the findings from previous Havrix and Epaxal studies 6,7,9-11,14. This gender-related difference in immunogenicity may have resulted from the confounding effect of body weight 10.…”

Section: Discussionsupporting

confidence: 92%

The Immunogenicity of a Single Dose of Hepatitis A Virus Vaccines (Havrix® and Epaxal®) in Korean Young Adults

et al. 2014

View full text Add to dashboard Cite

PurposeAssessing the immunogenicity of a single dose of hepatitis A virus (HAV) vaccines is important because some people receive only a single dose. However, previous studies have shown variable results and have not examined the effects of demographic characteristics other than gender. This study was performed to examine the immunogenicity of a single dose of HAV vaccine according to the vaccine type and demographic characteristics in young adults.Materials and MethodsSeronegative medical school students were randomly allocated to receive either Havrix or Epaxal.ResultsAfter approximately 11 months, the seroconversion rate in 451 participants was 80.7%. In men, the Havrix group showed a significantly higher seroconversion rate (81.9%) than the Epaxal group (69.2%), whereas both vaccine groups showed similarly high immunogenicity in women (Havrix: 90.1%, Epaxal: 92.9%; P for interaction=0.062). According to the results of a multivariate analysis, Epaxal showed significantly lower immunogenicity than Havrix only in men. Age, obesity, drinking, smoking, and follow-up time did not significantly affect seroconversion in either gender.ConclusionThe seroconversion rate of single-dose HAV vaccines was low in men, particularly in those who received Epaxal. Our results suggest that gender effects should be considered when comparing the immunogenicity of different HAV vaccines.

show abstract

Section: Discussionsupporting

confidence: 92%

The Immunogenicity of a Single Dose of Hepatitis A Virus Vaccines (Havrix® and Epaxal®) in Korean Young Adults

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Although virosomes can be produced from a variety of enveloped viruses, the influenza virus has been the dominant substrate for producing virosome-based vaccines [13]. The virosomal delivery platform benefited from an extensive human safety profile, as demonstrated over the last 20 years in adults as well as children, elderlies, and immune-compromised populations [14, 15]. Early efforts of conjugating virosomes with peptides derived from repeat region of Pf CSP and an ectodomain of the P. falciparum apical membrane antigen-1 ( Pf AMA1), a micronemal protein involved in merozoite invasion led to several clinical trials.…”

Section: Particulate Antigensmentioning

confidence: 99%

Particle-based platforms for malaria vaccines

Narum

Fleury³

et al. 2015

Vaccine

View full text Add to dashboard Cite

Recombinant subunit vaccines in general are poor immunogens likely due to the small size of peptides and proteins, combined with the lack or reduced presentation of repetitive motifs and missing complementary signal(s) for optimal triggering of the immune response. Therefore, recombinant subunit vaccines require enhancement by vaccine delivery vehicles in order to attain adequate protective immunity. Particle-based delivery platforms, including particulate antigens and particulate adjuvants, are promising delivery vehicles for modifying the way in which immunogens are presented to both the innate and adaptive immune systems. These particle delivery platforms can also co-deliver non-specific immunostimodulators as additional adjuvants. This paper reviews efforts and advances of the Particle-based delivery platforms in development of vaccines against malaria, a disease that claims over 600,000 lives per year, most of them are children under 5 years of age in sub-Sahara Africa.

show abstract

“…Four inactivated vaccines are currently widely available – in addition to other vaccines with more limited distribution – with well‐documented data showing these vaccines to be safe and highly immunogenic, with rapid seroconversion [11–13], proven protective efficacy and demonstrated field effectiveness. The use of these HepA vaccines is interchangeable with flexible schedules and they can be co‐administered or used in combinations.…”

Section: Hepatitis a Vaccinesmentioning

confidence: 99%

Has the time come to control hepatitis A globally? Matching prevention to the changing epidemiology

Hendrickx

Herck

Vorsters

et al. 2008

Journal of Viral Hepatitis

View full text Add to dashboard Cite

For the first time a global meeting on hepatitis A virus (HAV) infection as vaccine preventable disease was organized at the end of 2007. More than 200 experts from 46 countries gathered to investigate the changing global HAV epidemiology reflecting the increasing numbers of persons at risk for severe clinical disease and mortality from HAV infection. The benefits of childhood and adult hepatitis A (HepA) vaccination strategies and the data needed by individual countries and international health organizations to assess current HepA prevention strategies were discussed. New approaches in preventing HAV infection including universal HepA vaccination were considered. This introductory paper summarizes the major findings of the meeting and describes the changing epidemiology of HAV infections and the impact of HepA vaccination strategies in various countries. Implementation of HepA vaccination strategies should take into account the level of endemicity, the level of the socio-economic development and sanitation, and the risk of outbreaks. A stepwise strategy for introduction of HepA universal immunisation of children was recommended. This strategy should be based on accurate surveillance of cases and qualitative documentation of outbreaks and their control, secure political support on the basis of high-quality results, and comprehensive cost-effectiveness studies. The recognition of the need for increased global attention towards HepA prevention is an important outcome of this meeting.

show abstract

Rapid Antibody Response after Vaccination with a Virosomal Hepatitis A Vaccine

Abstract: Primary vaccination with this virosomal HAV vaccine is well tolerated and induces a rapid HAV-neutralizing antibody response resulting in seroprotection in all subjects within 10 days. In addition, the booster vaccination results in prolonged seroprotective antibody levels.

Cited by 20 publications

References 16 publications

The Immunogenicity of a Single Dose of Hepatitis A Virus Vaccines (Havrix® and Epaxal®) in Korean Young Adults

The Immunogenicity of a Single Dose of Hepatitis A Virus Vaccines (Havrix® and Epaxal®) in Korean Young Adults

Particle-based platforms for malaria vaccines

Has the time come to control hepatitis A globally? Matching prevention to the changing epidemiology

Contact Info

Product

Resources

About